Yesterday, we showed you how CRISPR gene editing has the potential to cure all diseases.
But curing existing diseases isn’t the only thing gene editing is capable of. It will also help prevent us from getting sick in the first place.
That’s why Jeff Brown, our go-to tech expert, says living to 120… and beyond… will soon be normal.
And the implications go beyond extending our lives here on Earth…
Gene editing could even help us push the boundaries of space exploration.
You’ll see how below…
I (Chris) promise you, understanding what this technology is all about will give you an edge over 99% of investors.
As Jeff has been telling his readers, it’s a tech mega-trend that will run for years… even decades.
It allows scientists to “cut” a genetic mutation out of our DNA code and replace it with a healthy, mutation-free version.
That’s what makes gene editing so revolutionary.
Most medicine today is reactive. You get sick. You get some symptoms. You go to your doctor. He treats you.
But with proactive, genetic-based medicine… you don’t have to wait until you get sick. Your doctor can head any illness off at the pass, so to speak.
And the key to this is our genome.
It’s our complete set of DNA.
With proactive medicine, a doctor can sequence your genome. Then he can figure out what diseases you’re likely to suffer from in the future…
And he can stop you from getting sick in the first place.
Jeff calls it the age of personalized medicine. Here he is with more on why it’s so revolutionary…
According to a British study, 10,000 people die of cancer each year in Britain because they’re diagnosed too late. And that’s just cancer. The trend is similar for HIV, Parkinson’s disease, and strokes.
But with proactive medicine, doctors use genetic sequencing to identify illnesses months – or even years – before symptoms show up.
This will allow doctors to identify therapies customized for each patient based on their unique genome. There will be no more wasting time with one-size-fits-all treatments that may not work and may cause bad side effects.
It’s a huge leap in medicine. And it could help save more lives than anything we’ve seen since we discovered antibiotics in the 1920s.
Even better, sequencing your genome is quickly getting cheaper – and more accessible.
It’s a genome sequencing company based in Danvers, Massachusetts.
It caught Jeff’s eye earlier this month when management dropped the price of sequencing the human genome from $999 to $599.
At $599, we’re getting to the point where your insurance company could cover whole genome sequencing in the near future.
And keep in mind, $599 is a massive drop from just two decades ago.
In 2000, the first whole genome sequencing cost $2.7 billion. A year later, the price had dropped to $100 million.
And Jeff expects the price to drop to $100 within the next two years. At that point, all insurance companies will cover sequencing. And the genetic revolution will be available on a mass scale.
The biggest challenge we face with space exploration right now is the high level of radiation it exposes our bodies to. (There’s 30 times the radiation in space as there is here on Earth.)
Radiation harms human DNA. This degrades astronauts’ nervous systems… as well as their mental and motor skills. It also ups their chance of getting cancer.
Recently, a group of high-school kids from Minnesota won a U.S. National Laboratory prize. They won it for their research into how CRISPR can protect astronauts’ DNA from the effects of radiation.
They used CRISPR to edit a yeast’s genome so scientists could analyze how the DNA would repair itself from mutations caused by radiation.
This shows just how easy this “software programming” for genes has become. Jeff…
These high-school kids used CRISPR technology and a handheld genetic sequencer that’s off the shelf. They didn’t need a million-dollar lab.
With CRISPR, we have turned human DNA into software code. The tools are so cheap and easy to use that there are no barriers to entry. That’s a recipe for exponential growth.
We’re entering a new “Genetic Age.” Editing our genes to prolong life and combat disease will become the norm.
It’s why Jeff expects an avalanche of investment dollars to flow into the best gene-editing stocks before 2019 is out.
Already, Jeff’s readers have racked up impressive gains from gene-editing stocks.
For instance, the top-performing recommendation at our Exponential Tech Investor advisory is a CRISPR gene-editing company. It’s up 250% since he recommended it in October 2016.
But as we mentioned earlier, this trend is just getting started.
There are many companies doing breakthrough work in gene editing. But because most of them are small startups, most folks don’t have access to them.
For five years, he’s been working on a system that makes investing in early-stage companies available to all investors… not just high-net-worth individuals.
And he’s hosting a free investor seminar all about it tonight at 8 p.m. ET.
As an angel investor, this is what Jeff does best. He has been a Silicon Valley insider for 30 years. In that time, he has backed over 100 technology startups… with a 95% success rate.
Quite simply, he’s a master at spotting the best early-stage companies – years before they go public.
And the strategy he’ll walk you through tonight is a chance for the average investor to reap these early-stage gains. We’re talking gains as high as 566%… 741%… even 1,008%.
I’ll be tuning in tonight. I hope you’ll join me. Save your spot with one-click registration right here.
Regards,
Chris Lowe
July 24, 2019
Lisbon, Portugal